drugset / Trial / NCT00248287
PhII ICb With/Without Erbitux in MBC Pts
Phase 2
Active not recruiting
154 enrolled
US Oncology Research
Bristol-Myers Squibb · collabPfizer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
Timeline
- Start
- 2005-07-28
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 2 unknown | — |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Comparator | Irinotecan | Small molecule | 90 mg/m2 | — |